ERCC1 and XRCC1 single nucleotide polymorphisms can guide treatment decision in patients with metastatic non-small cell lung cancer

Basit Öğe Kaydı
dc.contributor.authorDemirkazik, Ahmet
dc.contributor.authorIsikdogan, Abdurrahman
dc.contributor.authorInal, Ali
dc.contributor.authorKaraagac, Mustafa
dc.contributor.authorBozcuk, Hakan
dc.contributor.authorAkkuloglu, Tuba
dc.contributor.authorArtac, Mehmet
dc.date.accessioned2024-04-24T19:11:49Z
dc.date.available2024-04-24T19:11:49Z
dc.date.issued2020
dc.departmentDicle Üniversitesien_US
dc.description.abstractResults from studies in several cancers on single nucleotide polymorphisms (SNPs) suggest that DNA repair capacity may have prognostic implication for disease recur-rence, survival, and responses to treatment. This study aimed to evaluate the potential prognostic value of SNPs as biomarkers in patients with metastatic non-small cell lung cancer (mNSCLC) treated with platinum. Analysis of SNPs from peripheral blood cells was performed by polymerase chain reaction. Excision repair cross-comple-menting group 1 (ERCC1)-Asn118Asn, excision repair cross-complementing group 2 (ERCC2)-Lys751Gln, X-ray repair cross-complementing group 1 (XRCC1)-Arg-399Gln, and tumor protein 53 (TP53)-Arg72Pro polymorphisms were evaluated in conjunction with clinical and pathological parameters, and survival. The median pro-gression-free survival (PFS) and overall survival (OS) of 145 patients were 5.1 months and 30.9 months, respectively. In the univariate analysis ERCC1 genotype, XRCC1 genotype, and Eastern Cooperative Oncology Group Performance Status (ECOG-PS) were significant parameters for OS. In the multivariate analysis ERCC1 genotype, XRCC1 genotype, and ECOG-PS retained their significance. The median OS was 45.2 months for the ERCC1 normal (CC) and heterozygote (CT) genotypes, and 25.5 months for the ERCC1 mutant (TT) genotype. The median OS was 31.4 months for the XRCC1 normal (AA) and heterozygote (AG) genotypes, and 23.1 months for the XRCC1 mutant (GG) genotype. The median OS was 30,7 months for ECOG-PS? 1 and 10.2 months for ECOG-PS? 2. ERCC1 and XRCC1 genotypes, and ECOG-PS independently predicted OS in mNSCLC patients. Additional studies are needed for the further evaluation of potential prognostic SNPs in mNSCLCen_US
dc.identifier.doi10.5455/medscience.2019.08.9184
dc.identifier.endpage260en_US
dc.identifier.issn2147-0634
dc.identifier.issue1en_US
dc.identifier.startpage255en_US
dc.identifier.trdizinid370526
dc.identifier.urihttps://doi.org/10.5455/medscience.2019.08.9184
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/370526
dc.identifier.urihttps://hdl.handle.net/11468/28212
dc.identifier.volume9en_US
dc.indekslendigikaynakTR-Dizin
dc.language.isoenen_US
dc.relation.ispartofMedicine Science
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleERCC1 and XRCC1 single nucleotide polymorphisms can guide treatment decision in patients with metastatic non-small cell lung canceren_US
dc.titleERCC1 and XRCC1 single nucleotide polymorphisms can guide treatment decision in patients with metastatic non-small cell lung cancer
dc.typeArticleen_US

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu